share_log

Arcutis Biotherapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144

Arcutis Biotherapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144

Arcutis Biotherapeutics | 144：拟议出售证券
美股sec公告 ·  05/02 15:35
Moomoo AI 已提取核心信息
Arcutis Biotherapeutics, Inc. officer Todd Franklin Watanabe is set to sell 13,783 shares of common stock on 05/02/2024, as per the latest filing. The shares, valued at an aggregate market value of $120,432, were acquired through a restricted stock vest on 05/01/2024. This transaction follows a recent history of sales by Watanabe over the past three months, totaling 17,368 shares for gross proceeds of $191,868.
Arcutis Biotherapeutics, Inc. officer Todd Franklin Watanabe is set to sell 13,783 shares of common stock on 05/02/2024, as per the latest filing. The shares, valued at an aggregate market value of $120,432, were acquired through a restricted stock vest on 05/01/2024. This transaction follows a recent history of sales by Watanabe over the past three months, totaling 17,368 shares for gross proceeds of $191,868.
根据最新文件，Arcutis Biotherapeutics, Inc.高管渡边托德·富兰克林定于2024年2月5日出售13,783股普通股。这些股票的总市值为120,432美元，于2024年1月5日通过限制性股票背心收购。该交易遵循了渡边在过去三个月中的近期销售记录，共计17,368股股票，总收益为191,868美元。
根据最新文件，Arcutis Biotherapeutics, Inc.高管渡边托德·富兰克林定于2024年2月5日出售13,783股普通股。这些股票的总市值为120,432美元，于2024年1月5日通过限制性股票背心收购。该交易遵循了渡边在过去三个月中的近期销售记录，共计17,368股股票，总收益为191,868美元。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息